| Irene Dino Coon, PHARMD | |
|
10710 W Mcdowell Rd, Avondale, AZ 85392-5958 | |
| (623) 936-7234 | |
| Not Available |
| Full Name | Irene Dino Coon |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 10710 W Mcdowell Rd, Avondale, Arizona |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1760816847 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | S020108 (Arizona) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Irene Dino Coon, PHARMD 10710 W Mcdowell Rd, Avondale, AZ 85392-5958 Ph: (623) 936-8956 | Irene Dino Coon, PHARMD 10710 W Mcdowell Rd, Avondale, AZ 85392-5958 Ph: (623) 936-7234 |
News Archive
Starting this month, The Journal of Head Trauma Rehabilitation (JHTR)—in partnership with The Center For Outcome Measurement in Brain Injury (COMBI)—introduces a new feature designed to support effective and informed use of standardized assessments for evaluation of brain injury.
On Monday, November 18, 2019 the New York Academy of Sciences and the Critical Care and Resuscitation Research Program at NYU Langone will present a two part event titled What Happens When We Die? at the Academy's offices in downtown Manhattan.
Cadence Pharmaceuticals, Inc. today announced that its underwriters partially exercised their over-allotment option in connection with its previously announced public offering that priced on November 11, 2010, by purchasing an additional 1,000,000 shares of its common stock at a public offering price of $8.00 per share. Including the over-allotment shares purchased, Cadence sold a total of 12,500,000 shares in the offering, resulting in expected aggregate gross proceeds to the company of $100 million.
Scientists at the University of Alberta have shown that the drug remdesivir is highly effective in stopping the replication mechanism of the coronavirus that causes COVID-19, according to new research published today in the Journal of Biological Chemistry.
The U.S. Food and Drug Administration has approved colon cancer drug Erbitux to treat head and neck cancer after results of a large clinical trial showed the drug prolonged survival by 20 months.
› Verified 5 days ago
Brittney Lemming, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1575 N Dysart Rd, Avondale, AZ 85392 Phone: 623-925-0851 | |
Karen Anne Wolfson, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 10675 W Indian School Rd, Avondale, AZ 85392 Phone: 623-772-0502 | |
Megan Rhea, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 13055 W Rancho Santa Fe Blvd, Avondale, AZ 85392 Phone: 623-935-4022 Fax: 623-935-4149 | |
Dr. Erik Kirakosyan, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 10350 W Mcdowell Rd Apt 1211, Avondale, AZ 85392 Phone: 323-377-7643 | |
Keri M Romero, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 280 N Avondale Blvd, Avondale, AZ 85323 Phone: 623-882-2021 | |
Caitlin Saunders, PHARM D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 10705 W Indian School Rd, Avondale, AZ 85392 Phone: 623-877-3245 | |
Dr. Heather Bartelt, PHARM D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1459 N Dysart Rd, Avondale, AZ 85323 Phone: 623-882-3871 Fax: 623-882-3873 |